Provided by Tiger Trade Technology Pte. Ltd.

Alkermes PLC

40.11
-1.3350-3.22%
Post-market: 40.110.00000.00%19:30 EDT
Volume:3.25M
Turnover:130.30M
Market Cap:6.73B
PE:103.31
High:41.26
Open:41.10
Low:39.11
Close:41.45
52wk High:55.67
52wk Low:27.00
Shares:167.76M
Float Shares:155.00M
Volume Ratio:1.41
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3882
EPS(LYR):1.43
ROE:3.85%
ROA:4.20%
PB:3.72
PE(LYR):28.05

Loading ...

Alkermes - Phase 2 Study of Alks 7290 in Adults with Adhd Enrolling, Data Expected in 2027

THOMSON REUTERS
·
Sep 21

Alkermes Files Form 3 for Director Anne Clem Whitaker`

Reuters
·
Sep 19

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Twist Bioscience (TWST) and Medpace Holdings (MEDP)

TIPRANKS
·
Sep 17

Alkermes Appoints Anne Whitaker to Board of Directors

Reuters
·
Sep 16

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

THOMSON REUTERS
·
Sep 16

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS
·
Sep 10

Mizuho survey shows no consensus into Alkermes ADHD data

TIPRANKS
·
Sep 05

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

Reuters
·
Sep 04

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874

Reuters
·
Sep 02

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

Reuters
·
Aug 25

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS
·
Aug 25

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

Reuters
·
Aug 18

Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment

Reuters
·
Aug 12

Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 12

Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing

THOMSON REUTERS
·
Aug 12

The Race to Come up with the Next Big Sleep Drug

Dow Jones
·
Aug 07

Alkermes EVP, CLO David Joseph Gaffin Sells 2,034 Shares for $98,821.72

Reuters
·
Aug 04

Alkermes Amends 8-K to Disclose CEO Blair Jackson Pay Package Including $5 Million Equity Award

Reuters
·
Aug 04

Alkermes' Core Business Backed Q2 Beat, Orexin Pipeline to Serve as Catalyst, RBC Says

MT Newswires Live
·
Jul 29

Alkermes Plc : Jefferies Raises Target Price to $72 from $65

THOMSON REUTERS
·
Jul 29